NCT00501969 - An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease | Biotech Hunter

Enrollment

395

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Advanced Stage Parkinson's Disease

Interventions

DRUG

Rotigotine

"Rotigotine trans-dermal patches once daily:~20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) 50 cm2 (10 mg/24 hours) 60 cm2 (12 mg/24 hours) 70 cm2 (14 mg/24 hours) 80 cm2 (16 mg/24 hours)"

Trial Locations (53)

Unknown

Bedford Park

Concord

Darlinghurst

East Gosford

Westmead

Innsbruck

Zagreb

Brno

Ostrava - Poruba

Pardubice

Pilsen

Prague

Oulu

Pori

Aix-en-Provence

Lille

Lyon

Aachen

Bochum

Budapest

Miskolc

Pécs

Petah Tikva

Tel Aviv

Milan

Napoli

Padua

Pisa

Pozzilli

Roma

Auckland

Christchurch

Wellington

Bergen

Stavanger

Trondheim

Tønsberg

Gdansk

Krakow

Lublin

Mosina k/Poznania

Olsztyn

Warsaw

Cape Town

Pretoria

Tygerberg

Barcelona

Donostia / San Sebastian

Madrid

Stockholm

Blackpool

Glasgow

Sheffield